ES2184126T3 - Derivados de 3-mercaptoacetilamino-1,5-sustituido-2-oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz. - Google Patents

Derivados de 3-mercaptoacetilamino-1,5-sustituido-2-oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz.

Info

Publication number
ES2184126T3
ES2184126T3 ES97935308T ES97935308T ES2184126T3 ES 2184126 T3 ES2184126 T3 ES 2184126T3 ES 97935308 T ES97935308 T ES 97935308T ES 97935308 T ES97935308 T ES 97935308T ES 2184126 T3 ES2184126 T3 ES 2184126T3
Authority
ES
Spain
Prior art keywords
oxo
substituted
useful
derivatives
mercaptoacetilamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97935308T
Other languages
English (en)
Inventor
Alan M Warshawsky
Gary A Flynn
Meena V Patel
Douglas W Beight
Joseph P Burkhart
Jiu-Tsair Tsay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2184126T3 publication Critical patent/ES2184126T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LAS INVENCION SE REFIERE A CIERTOS NUEVOS DERIVADOS DEL 3MERCAMPTOACETILAMINO-1,5-SUSTITUIDO-2-OXO-ACEPAN UTILES COMO INHIBIDORES DE LA METALOPROTEINASA MATRICIAL. TAMBIEN SE PRESENTAN COMPOSICIONES QUE CONTIENEN LOS COMPUESTOS ASI COMO PROCEDIMIENTOS PARA TRATAR DIFERENTES ESTADOS PATOLOGICOS QUE RESPONDEN A LA INHIBICION DE LA METALOPROTEINASA MATRICIAL.
ES97935308T 1996-09-19 1997-08-04 Derivados de 3-mercaptoacetilamino-1,5-sustituido-2-oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz. Expired - Lifetime ES2184126T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19

Publications (1)

Publication Number Publication Date
ES2184126T3 true ES2184126T3 (es) 2003-04-01

Family

ID=24889504

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97935308T Expired - Lifetime ES2184126T3 (es) 1996-09-19 1997-08-04 Derivados de 3-mercaptoacetilamino-1,5-sustituido-2-oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz.

Country Status (20)

Country Link
EP (1) EP0928291B1 (es)
JP (1) JP3962091B2 (es)
KR (1) KR100545460B1 (es)
CN (1) CN1150205C (es)
AR (1) AR009363A1 (es)
AT (1) ATE229034T1 (es)
AU (1) AU718055B2 (es)
BR (1) BR9713207A (es)
CA (1) CA2266759C (es)
DE (1) DE69717647T2 (es)
DK (1) DK0928291T3 (es)
ES (1) ES2184126T3 (es)
HU (1) HUP9904165A3 (es)
IL (2) IL129035A0 (es)
NO (1) NO991316L (es)
NZ (1) NZ334490A (es)
PT (1) PT928291E (es)
TW (1) TW445262B (es)
WO (1) WO1998012211A1 (es)
ZA (1) ZA978307B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
WO2000040553A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
WO2000040577A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
EP1229914A4 (en) 1999-11-10 2004-06-23 Smithkline Beecham Corp PROTEASE INHIBITORS
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
AU4344101A (en) 2000-03-21 2001-10-03 Smithkline Beecham Corp Protease inhibitors
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
WO2018220032A1 (en) 2017-05-31 2018-12-06 B.R.A.I.N. Biotechnology Research And Information Network Ag Optimization of the expression of serine proteases in host cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358660B1 (en) * 1987-03-17 1994-05-25 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
JPH07304746A (ja) * 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピンカルボン酸誘導体
ES2133807T3 (es) * 1994-10-05 1999-09-16 Darwin Discovery Ltd Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
NO991316L (no) 1999-05-18
IL129035A0 (en) 2000-02-17
CN1234039A (zh) 1999-11-03
CN1150205C (zh) 2004-05-19
JP3962091B2 (ja) 2007-08-22
ATE229034T1 (de) 2002-12-15
AU718055B2 (en) 2000-04-06
DE69717647D1 (de) 2003-01-16
JP2001501926A (ja) 2001-02-13
NZ334490A (en) 2000-08-25
AR009363A1 (es) 2000-04-12
CA2266759A1 (en) 1998-03-26
KR20000036246A (ko) 2000-06-26
HUP9904165A2 (hu) 2000-03-28
ZA978307B (en) 1998-03-19
BR9713207A (pt) 2000-04-04
IL129035A (en) 2006-12-10
NO991316D0 (no) 1999-03-18
HK1020741A1 (en) 2000-05-19
AU3827897A (en) 1998-04-14
KR100545460B1 (ko) 2006-01-24
WO1998012211A1 (en) 1998-03-26
DE69717647T2 (de) 2003-09-25
DK0928291T3 (da) 2003-03-17
CA2266759C (en) 2004-10-26
EP0928291A1 (en) 1999-07-14
PT928291E (pt) 2003-03-31
HUP9904165A3 (en) 2002-01-28
TW445262B (en) 2001-07-11
EP0928291B1 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
ES2196378T3 (es) Proceso para mezcla de aceites de petroleo potencialmente incompatibles.
SV1995000074A (es) Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de la matriz
BG104247A (bg) Производни на резорцинола
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
AR011539A1 (es) DERIVADOS DE BENZOILO-3-HETEROCICLIL-SUSTITUIDOS, PROCEDIMIENTO PARA SU PREPARACIoN,COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHO PROCEDIMIENTO, COMPOSICIONES QUE COMPRENDEN DICHOS DERIVADOS, Y PROCEDIMIENTO PARA SU PREPARACIoN, PROCEDIMIENTO PARA COMBATIR VEGETACIoN NO DESADA QUE LOS EMPLEA Y SU
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2155601T3 (es) Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
PA8541601A1 (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
ES2151277T3 (es) Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
MXPA94001345A (es) Derivados de poliamina como agentes radioprotectores.
ES2124069T3 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BR9713207A (pt) Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz
MX9305093A (es) Nuevos derivadosindano-2 mercaptoacetilamina triciclicos 2-sustituidos, utiles como inhibidores de la encefalinasa.
PA8486701A1 (es) Antagonistas de 5ht1 para terapia antidepresiva
UY26265A1 (es) Compuestos calciolíticos
ES2153875T3 (es) Agentes antitromboticos.
SV1997000035A (es) Acetilenos de biaril como inhibisores de matrices metaloproteasas